Compare WEAV & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | INDP |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 350.4M |
| IPO Year | 2021 | 2021 |
| Metric | WEAV | INDP |
|---|---|---|
| Price | $7.19 | $2.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 152.2K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $0.92 |
| 52 Week High | $8.28 | $10.91 |
| Indicator | WEAV | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 68.86 | 44.26 |
| Support Level | $6.94 | $2.42 |
| Resistance Level | $7.31 | $3.11 |
| Average True Range (ATR) | 0.31 | 0.22 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 72.21 | 11.11 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.